ANIP
ANI Pharmaceuticals Inc
78.90$
+3.6%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 77.2% | 67.5% | 31.9% | 31.9% | 35.5% | 41.1% | 36.9% | 41.7% | 45.3% | 57.5% | 41.1% | 52.3% | |
| 64.1% | 54.2% | 8.5% | 7.6% | 10.0% | 13.6% | 1.7% | 13.0% | 6.3% | 24.4% | 11.3% | 19.8% | |
| 64.1% | 54.2% | 8.5% | 7.6% | 10.0% | 13.6% | 1.7% | 13.0% | 6.3% | 24.4% | 11.8% | 19.8% | |
| 6.6% | 7.7% | 14.2% | 14.3% | 15.1% | 15.8% | 20.8% | 16.7% | 21.8% | 17.9% | 17.3% | 19.5% | |
| 2.9% | 4.7% | 8.1% | 9.2% | 9.4% | 10.5% | 13.2% | 10.6% | 13.9% | 12.3% | 10.7% | 9.9% | |
| 2.0% | 2.5% | 3.4% | 5.0% | 8.8% | 8.9% | 8.9% | 6.8% | 5.7% | – | – | – | |
| 0.7% | 0.6% | 0.6% | 0.4% | 0.8% | 0.8% | 0.8% | 3.6% | 3.7% | 3.1% | 4.7% | 4.3% | |
| 16.0% | 23.3% | 54.4% | 55.8% | 46.8% | 39.5% | 40.9% | 38.1% | 33.1% | 23.1% | 42.2% | 33.3% | |
| 47.0% | 43.9% | 47.5% | 57.6% | 54.2% | 53.4% | 57.6% | 53.5% | 55.5% | 49.4% | 66.6% | 62.5% | |
| 5.0% | 4.1% | 9.9% | 9.5% | 38.4% | 13.5% | 17.0% | 11.3% | 13.1% | 16.1% | 15.1% | 19.3% | |
| 40.4% | 39.8% | 37.4% | 0.8% | 26.9% | 2.2% | 2.9% | 0.1% | 0.1% | 0.1% | 0.7% | 1.2% | |
| 1.0% | 0.7% | 1.0% | 0.9% | 2.1% | 3.2% | 2.4% | 3.0% | 3.9% | 4.1% | 3.6% | 4.3% | |
| 42.0% | 39.8% | 37.4% | 31.1% | 15.6% | 38.5% | 37.4% | 37.1% | 37.6% | 31.5% | 47.9% | 41.6% | |
| 53.0% | 56.1% | 52.5% | 42.4% | 45.8% | 46.6% | 42.4% | 46.5% | 44.5% | 50.6% | 33.4% | 37.5% | |
| -7.5% | -1.5% | -0.9% | -1.0% | 2.7% | 3.8% | -1.1% | -6.2% | -12.8% | -8.9% | -7.8% | -1.6% | |
| 4.2% | 4.1% | 3.6% | 2.8% | 2.7% | 2.6% | 2.6% | 1.6% | 2.1% | 2.0% | 1.5% | 1.5% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.